For over a decade preclinical progress in cancer biology, genetics, tumor profiling, and biotechnology have led to the successful development of a greatly expanded spectrum of biologically active agents that effectively target cancer-related proteins and pathways that improve individual antitumor effects with decreased toxicity for selective patients. However, compared to the well characterized and documented lung toxicities of the conventional chemotherapeutic agents, these newer agents continue to exhibit a reduced but significant incidence of potentially toxic effects impacting normal lung tissues. In the next decade one can expect a continued translational development of the rich pipeline of novel mutation targeted anticancer agents designed to affect specific tumor and stromal metabolic aberrances. Many of these newer agents preferentially target genetic and molecular pathways that are unique to tumor tissues, thus they can potentially be given in high doses before serious side effects appear. In this chapter the spectrum of lung toxicities of the more traditional chemotherapeutic agents are discussed with some focus on redox-directed chemotherapeutics and their related lung toxicities, as best exemplified by bleomycin. Specific lung manifestations of selected conventional and the newer personalized molecularly targeted entities that are increasingly providing complementary and novel cancer chemotherapeutic approaches are discussed. Finally, this review highlights clinical approaches toward the diagnosis and treatment of lung toxicities occurring as unwanted side effects of cancer chemotherapy.
|Original language||English (US)|
|Title of host publication||Respiratory Toxicology|
|Number of pages||34|
|State||Published - Aug 12 2010|
ASJC Scopus subject areas